Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome (Q46514791)

22 December 2017

title

Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome (English)

1 reference

22 December 2017

polycystic ovary syndrome

1 reference

1 reference

1 reference

1 reference

Y M Hwu

1

1 reference

22 December 2017

S Y Lin

2

1 reference

22 December 2017

W Y Huang

3

1 reference

22 December 2017

M H Lin

4

1 reference

22 December 2017

R K K Lee

5

1 reference

22 December 2017

publication date

1 July 2005

1 reference

22 December 2017

International Journal of Gynecology and Obstetrics

published in

1 reference

22 December 2017

volume

90

1 reference

22 December 2017

issue

1

1 reference

22 December 2017

page(s)

39-43

1 reference

22 December 2017

The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

Metformin directly inhibits androgen production in human thecal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.IJGO.2005.04.004

10.1016/J.IJGO.2005.04.004

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

PubMed ID

15921686

1 reference

22 December 2017